Clinical significance of N-terminal-probrain natriuretic peptide in hypertrophic cardiomyopathy

Heart and Vessels

Volumn 22, Issue 5, 2007, Pages 322-327

  Efthimiadis, Georgios K ^a,b   Hitoglou Makedou, Areti ^a   Giannakoulas, Georgios ^a   Mitakidou, Anastasia ^a   Karamitsos, Theodoros ^a   Karvounis, Haralambos ^a   Mochlas, Sotirios ^a   Styliadis, Ioannis ^a   Stefanidis, Haris ^a   Parcharidis, Georgios ^a   Louridas, Georgios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NONE   (Greece)

Author keywords

Congestive heart failure; Hypertrophic cardiomyopathy; N Terminal probrain natriuretic peptide

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; VERAPAMIL;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FUNCTIONAL STATUS; HEART LEFT ATRIUM; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE WALL; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMMUNOASSAY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT REFERRAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIOMYOPATHY, HYPERTROPHIC; COHORT STUDIES; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NATRIURETIC PEPTIDE, BRAIN; PROTEIN STRUCTURE, TERTIARY; REGRESSION ANALYSIS;

EID: 34648820495     PISSN: 09108327     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00380-007-0976-y     Document Type: Article

References (38)

1. BJ Maron 1997 Hypertrophic cardiomyopathy Lancet 350 127-133 9228976 10.1016/S0140-6736(97)01282-8 1:STN:280:ByiA2s3pt1U%3D
2. BJ Maron JM Gardin JM Flack SS Gidding TT Kurosaki DE Bild 1995 Prevalence of hypertrophic cardiomyopathy in a general population of young adults Circulation 92 785-789 7641357 1:STN:280:ByqA28fotFQ%3D
3. A Abchee AJ Marian 1997 Prognostic significance of beta-myosin heavy chain mutations is reflective of their hypertrophic expressivity in patients with hypertrophic cardiomyopathy J Invest Med 45 191-196 1:STN:280:ByiB1MfovFM%3D
4. JC Moolman VA Corfield B Posen K Ngumbela C Seidman PA Brink H Watkins 1997 Sudden death due to troponin T mutations J Am Coll Cardiol 29 549-555 9060892 10.1016/S0735-1097(96)00530-X 1:STN:280:ByiB3MvltFY%3D
5. BJ Maron I Olivotto P Spirito SA Casey P Bellone TE Gohman KJ Graham DA Burton F Cecchi 2000 Epidemiology of hypertrophic cardiomyopathy-related death: Revisited in a large nonreferral-based patient population Circulation 102 858-864 10952953 1:STN:280:DC%2BD3cvhvFWhuw%3D%3D
6. SS Lele HL Thomson H Seo I Belenkie WJ McKenna MP Frenneaux 1995 Exercise capacity in hypertrophic cardiomyopathy: Role of stroke volume limitation, heart rate, and diastolic filling characteristics Circulation 92 2886-2894 7586256 1:STN:280:BymD2s7jtFE%3D
7. MP Frenneaux A Porter AL Caforio H Odawara PJ Counihan WJ McKenna 1992 Determinants of exercise capacity in hypertrophic cardiomyopathy J Am Coll Cardiol 19 1521-1526
8. P Nihoyannopoulos G Karatasakis M Frenneaux WJ McKenna CM Oakley 1992 Diastolic function in hypertrophic cardiomyopathy: Relation to exercise capacity J Am Coll Cardiol 19 536-540 1538006 1:STN:280:By2C28nhslM%3D
9. C Briguori S Betocchi M Romano F Manganelli M Angela Losi Q Ciampi R Gottilla R Lombardi M Condorelli M Chiariello 1999 Exercise capacity in hypertrophic cardiomyopathy depends on left ventricular diastolic function Am J Cardiol 84 309-315 10496441 10.1016/S0002-9149(99)00282-9 1:STN:280:DyaK1MvisVOlsg%3D%3D
10. BJ Maron P Spirito KJ Green YE Wesley RO Bonow J Arce 1987 Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy J Am Coll Cardiol 10 733-742 3655141 1:STN:280:BieD3cfmvFY%3D
11. PA McCullough KR Sandberg 2003 Sorting out the evidence on natriuretic peptides Rev Cardiovasc Med 4 Suppl 4 S13-S19 14564224
12. AM Richards R Doughty MG Nicholls S MacMahon N Sharpe J Murphy EA Espiner C Frampton TG Yandle 2001 Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group J Am Coll Cardiol 37 1781-1787 11401111 10.1016/S0735-1097(01)01269-4 1:CAS:528:DC%2BD3MXltVGhsLw%3D
13. V Kirk M Bay J Parner K Krogsgaard TM Herzog S Boesgaard C Hassager OW Nielsen J Aldershvile H Nielsen 2004 N-terminal proBNP and mortality in hospitalized patients with heart failure and preserved vs. reduced systolic function: Data from the prospective Copenhagen Hospital Heart Failure Study (CHHF) Eur J Heart Fail 6 335-341 14987585 10.1016/ j.ejheart.2004.01.002 1:CAS:528:DC%2BD2cXhsFWqsLY%3D
14. P Bettencourt A Azevedo J Pimenta F Frioes S Ferreira A Ferreira 2004 N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients Circulation 110 2168-2174 15451800 10.1161/01.CIR.0000144310.04433.BE 1:CAS:528:DC%2BD2cXotFGksLk%3D
15. C Fisher C Berry L Blue JJ Morton J McMurray 2003 N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure Heart 89 879-881 12860863 10.1136/heart.89.8.879 1:STN:280:DC%2BD3szjtVOqtA%3D%3D
16. RS Gardner F Ozalp AJ Murday SD Robb TA McDonagh 2003 N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure Eur Heart J 24 1735-1743 14522568 10.1016/j.ehj.2003.07.005 1:CAS:528:DC%2BD3sXns1Krt74%3D
17. HG Klues A Schiffers BJ Maron 1995 Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: Morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients J Am Coll Cardiol 26 1699-1708 7594106 10.1016/0735-1097(95)00390-8 1:STN:280:BymD1czlsVE%3D
18. BJ Maron 2002 Hypertrophic cardiomyopathy: A systematic review JAMA 287 1308-1320 11886323 10.1001/jama.287.10.1308
19. MS Maron I Olivotto S Betocchi SA Casey JR Lesser MA Losi F Cecchi BJ Maron 2003 Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy N Engl J Med 348 295-303 12540642 10.1056/NEJMoa021332
20. S Sharma P Elliott G Whyte S Jones N Mahon B Whipp WJ McKenna 2000 Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy Am J Cardiol 86 162-168 10913477 10.1016/S0002-9149(00)00854-7 1:STN:280:DC%2BD3czpvFGrtg%3D%3D
21. BJ Maron P Spirito 1998 Implications of left ventricular remodeling in hypertrophic cardiomyopathy Am J Cardiol 81 1339-1344 9631972 10.1016/ S0002-9149(98)00164-7 1:STN:280:DyaK1c3ptlOgsQ%3D%3D
22. DJ Sahn A DeMaria J Kisslo A Weyman 1978 Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements Circulation 58 1072-1083 709763 1:STN:280:CSaD2czpsFU%3D
23. JA Panza RK Petrone L Fananapazir BJ Maron 1992 Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy J Am Coll Cardiol 19 91-99 1729351 1:STN:280:By2C3crmtFI%3D
24. GK Efthimiadis G Giannakoulas DG Parharidou HI Karvounis ST Mochlas IH Styliadis S Gavrielides KD Gemitzis GD Giannoglou GE Parharidis GE Louridas 2006 Prevalence of systolic impairment in an unselected regional population with hypertrophic cardiomyopathy Am J Cardiol 98 1269-1272 17056344 10.1016/j.amjcard.2006.05.063
25. Roche Diagnostics 2002 ProBrain natriuretic peptide package insert Roche Diagnostics Indianapolis
26. Biosite 2002 TriageBNP package insert Biosite San Diego
27. K Ogino K Ogura T Kinugawa S Osaki M Kato Y Furuse Y Kinugasa Y Tomikura O Igawa I Hisatome C Shigemasa 2004 Neurohumoral profiles in patients with hypertrophic cardiomyopathy: Differences to hypertensive left ventricular hypertrophy Circ J 68 444-450 15118286 10.1253/circj.68.444
28. BJ Maron VN Tholakanahalli AG Zenovich SA Casey D Duprez DM Aeppli JN Cohn 2004 Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy Circulation 109 984-989 14967727 10.1161/01.CIR.0000117098.75727.D8 1:CAS:528:DC%2BD2cXhsFeisbk%3D
29. T Nakamura K Sakamoto T Yamano M Kikkawa K Zen T Hikosaka T Kubota A Azuma T Nishimura 2002 Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with nonobstructive hypertrophic cardiomyopathy J Am Coll Cardiol 39 1657-1663 12020494 10.1016/S0735-1097(02)01813-2 1:CAS:528:DC%2BD38XktlGquro%3D
30. Y Mizuno M Yoshimura E Harada M Nakayama T Sakamoto Y Shimasaki H Ogawa K Kugiyama Y Saito K Nakao H Yasue 2000 Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy Am J Cardiol 86 1036-1040 11053725 10.1016/S0002-9149(00)01147-4 1:CAS:528:DC%2BD3cXnsFWqsb8%3D A11
31. C Briguori S Betocchi F Manganelli B Gigante MA Losi Q Ciampi R Gottilla A Violante CG Tocchetti M Volpe M Chiariello 2001 Determinants and clinical significance of natriuretic peptides in hypertrophic cardiomyopathy Eur Heart J 22 1328-1336 11465965 10.1053/euhj.2000.2535 1:STN:280:DC%2BD3Mvhs12ksw%3D%3D
32. K Hasegawa H Fujiwara K Doyama M Miyamae T Fujiwara S Suga M Mukoyama K Nakao H Imura S Sasayama 1993 Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy Circulation 88 372-380 8339400 1:STN:280:ByyA3sfosFM%3D
33. PJ Hunt AM Richards MG Nicholls TG Yandle RN Doughty EA Espiner 1997 Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment Clin Endocrinol (Oxf) 47 287-296 10.1046/j.1365-2265.1997.2361058.x 1:CAS:528:DyaK2sXms1Shu7w%3D
34. S Masson T Vago G Baldi M Salio N De Angelis E Nicolis AP Maggioni R Latini G Norbiato M Bevilacqua 2002 Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure Clin Chem Lab Med 40 761-763 12392300 10.1515/CCLM.2002.130 1:CAS:528:DC%2BD38XosFygurc%3D
35. TJ Wang MG Larson D Levy EP Leip EJ Benjamin PW Wilson P Sutherland T Omland RS Vasan 2002 Impact of age and sex on plasma natriuretic peptide levels in healthy adults Am J Cardiol 90 254-258 12127613 10.1016/ S0002-9149(02)02464-5 1:CAS:528:DC%2BD38XlsVKrurg%3D
36. J Li L Wang 2006 B-type natriuretic peptide levels in patients with paroxysmal lone atrial fibrillation Heart Vessels 21 137-140 16715186 10.1007/s00380-005-0884-y
37. E Arteaga AQ Araujo P Buck BM Ianni R Rabello C Mady 2005 Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy Am Heart J 150 1228-1232 16338263 10.1016/ j.ahj.2005.02.045 1:CAS:528:DC%2BD2MXhtlais7rL
38. R Thaman MT Esteban S Barnes JR Gimeno B Mist R Murphy PO Collinson WJ McKenna PM Elliott 2006 Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy Am J Cardiol 98 515-519 16893708 10.1016/ j.amjcard.2006.02.057 1:CAS:528:DC%2BD28XotFKisbg%3D